Cue Biopharma (CUE) vs Precision BioSciences (DTIL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Precision BioSciences (DTIL) has outperformed Cue Biopharma (CUE) over the past year, gaining 10.0% versus a loss of 0.2%. Over five years, CUE leads with a -94.0% price change compared with -97.9% for DTIL. Precision BioSciences is the larger company by market cap ($172.5 million vs $163.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | DTIL |
|---|---|---|
| Share price | $22.51 | $6.25 |
| Market cap | $163.52M | $172.51M |
| 1-day change | -2.72% | +0.81% |
| YTD return | +146.01% | +50.24% |
| 1-year return | -0.22% | +10.04% |
| 5-year return | -94.04% | -97.87% |
| EPS (TTM) | $-29.59 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $9.62 |
| 52-week low | $4.98 | $3.53 |
| Distance from 52-week high | -50.53% | -35.03% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +290.94% | +370.40% |
| Average volume | 269.82K | 295.49K |
| Shares outstanding | 7.26M | 27.60M |
| Employees | 29 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DTIL has outperformed CUE by 10.3 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 67 employees
CUE vs DTIL FAQ
Which is bigger, Cue Biopharma or Precision BioSciences?
Precision BioSciences (DTIL) is larger, with a market capitalization of $172.51M compared with $163.52M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CUE or DTIL?
DTIL returned +10.04% over the past 12 months, compared with -0.22% for CUE (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Precision BioSciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Cue Biopharma and Biotechnology: Biological Products (No Diagnostic Substances) for Precision BioSciences.